CAGR
Cagrilintide
A synthetic analogue of human amylin, acylated with a fatty diacid on a lysine side chain. It acts at the amylin receptors, which are formed when the calcitonin receptor associates with a receptor activity-modifying protein. It is not a GLP-1 analogue and does not share their backbone, which is why it is studied alongside them rather than as one of them.
Cagrilintide has 39 registered human studies on ClinicalTrials.gov, reaching phase 3, covering 23,728 planned or enrolled participants across the 39 studies that published a figure. No FDA-approved product contains Cagrilintide. 90 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Cagrilintide; the registry search is fuzzy, so every match is re-checked. None of this says whether Cagrilintide works or is safe.
FDA status
Research only
Human studies
39
Furthest phase
Phase 3
Papers, 10 yr
90
Readership
2,936
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Reached phase 3 or 4, not approved
39
Registered human studies
Phase 3
Furthest phase reached
23,728
Planned or enrolled participants, across 39 studies that published a figure
None
No FDA-approved product contains it
42 loose registry matches were checked and 39 confirmed — 3 named something else and were discarded. We count a study only when Cagrilintide is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Cagrilintide is, and what it has been studied for
Cagrilintide is classified by ChEMBL as a protein, and appears in trial registrations under NNC0174-0833. Its FDA substance identifier is AO43BIF1U8.
Across 39 registered trials, it has been studied in Obesity, Overweight, Type 2 Diabetes and Type 2 Diabetes Mellitus. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Novo Nordisk A/S. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Cagrilintide reached Phase 3 across 39 registered trials.
No FDA-approved product contains Cagrilintide. A compound can stop at any rung for commercial reasons as easily as scientific ones, and the registry does not record which.
Is anyone studying Cagrilintide?
Papers published each year that name Cagrilintide in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 0 | 0 | Yes |
| 2018 | 0 | 0 | Yes |
| 2019 | 0 | 0 | Yes |
| 2020 | 0 | 0 | Yes |
| 2021 | 8 | 2 | Yes |
| 2022 | 6 | 1 | Yes |
| 2023 | 5 | 8 | Yes |
| 2024 | 14 | 13 | Yes |
| 2025 | 30 | 7 | Yes |
| 2026 | 34 | 8 | No |
90 papers and 39 registered trials between 2017 and 2026. A paper counts when “Cagrilintide” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Cagrilintide
90 indexed papers name Cagrilintide in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
- Development of Cagrilintide, a Long-Acting Amylin Analogue
- Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis
Collected 2026-08-02from PubMed, phrase-matched on “Cagrilintide” in title and abstract. Run the same search.
About Cagrilintide
A synthetic analogue of human amylin, acylated with a fatty diacid on a lysine side chain. It acts at the amylin receptors, which are formed when the calcitonin receptor associates with a receptor activity-modifying protein. It is not a GLP-1 analogue and does not share their backbone, which is why it is studied alongside them rather than as one of them.
- Also known as
- AM833 · NNC0174-0833
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.